Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling

被引:17
|
作者
Bogaards, JJP [1 ]
Freidig, AP [1 ]
van Bladeren, PJ [1 ]
机构
[1] TNO, Nutr & Food Res, Div Toxicol, NL-3700 AJ Zeist, Netherlands
关键词
isoprene; metabolism; cytochrome P450; glutathione S-transferase; epoxide hydrolase; PBPK modelling;
D O I
10.1016/S0009-2797(01)00276-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present study was designed to explain the differences in isoprene toxicity between mouse and rat based on the liver concentrations of the assumed toxic metabolite isoprene diepoxide. In addition, extrapolation to the human situation was attempted. For this purpose, enzyme kinetic parameters K-m and V-max were determined in vitro in mouse, rat and human liver microsomes/cytosol for the cytochrome P450-mediated formation of isoprene mono- and diepoxides, epoxide hydrolase mediated hydrolysis of isoprene mono- and diepoxides, and the glutathione S-transferases mediated conjugation of isoprene monoepoxides. Subsequently, the kinetic parameters were incorporated into a physiologically-based pharmacokinetic model, and species differences regarding isoprene diepoxide levels were forecasted. Almost similar isoprene diepoxide liver and lung concentrations were predicted in mouse and rat, while predicted levels in humans were about 20-fold lower. However, when interindividual variation in enzyme activity was introduced in the human model, the levels of isoprene diepoxide changed considerably. It was forecasted that in individuals having both an extensive oxidation by cytochrome P450 and a low detoxification by epoxide hydrolase, isoprene diepoxide concentrations in the liver increased to similar concentrations as predicted for the mouse. However, the interpretation of the latter finding for human risk assessment is ambiguous since species differences between mouse and rat regarding isoprene toxicity could not be explained by the predicted isoprene diepoxide concentrations. We assume that other metabolites than isoprene diepoxide or different carcinogenic response might play a key role in determining the extent of isoprene toxicity. In order to confirm this, in vivo experiments are required in which isoprene epoxide concentrations will be established in rats and mice. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:247 / 265
页数:19
相关论文
共 50 条
  • [41] Metabolic profiles for the pyrrolizidine alkaloid neopetasitenine and its metabolite petasitenine in humans extrapolated from rat in vivo and in vitro data sets using a simplified physiologically based pharmacokinetic model
    Yanagi, Mayu
    Kamiya, Yusuke
    Murayama, Norie
    Banju, Kaito
    Shimizu, Makiko
    Yamazaki, Hiroshi
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2021, 46 (09): : 391 - 399
  • [42] Quantitative Analysis of Complex DrugeDrug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data
    Kim, Soo-Jin
    Toshimoto, Kota
    Yao, Yoshiaki
    Yoshikado, Takashi
    Sugiyama, Yuichi
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) : 2715 - 2726
  • [43] A PRIORI PREDICTION OF CYP3A VICTIM DRUG-DRUG INTERACTION OF MK-1 AND DILTIAZEM USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK): QUALIFICATION USING CLINICAL DATA
    Gibson, Christopher
    Hartmann, Georgy
    Ma, Bennett
    Chain, Anne
    Smith, Sean
    Forman, Mark
    Datta, Sandip
    Bateman, Thomas
    Li, Ying
    Khalilieh, Sauzanne
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S87 - S87
  • [44] In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human
    Alsmadi, Mo'tasem M.
    Alzughoul, Saja B.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2023, 44 (03) : 221 - 244
  • [45] A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept
    Sugiyama, Yuichi
    Aoki, Yasunori
    DRUG METABOLISM AND DISPOSITION, 2023, 51 (09) : 1067 - 1076
  • [46] Defining in vivo dose-response curves for kidney DNA adduct formation of aristolochic acid I in rat, mouse and human by an in vitro and physiologically based kinetic modeling approach
    Abdullah, Rozaini
    Wesseling, Sebastiaan
    Spenkelink, Bert
    Louisse, Jochem
    Punt, Ans
    Rietjens, Ivonne M. C. M.
    JOURNAL OF APPLIED TOXICOLOGY, 2020, 40 (12) : 1647 - 1660
  • [47] Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling ? A case study of doxorubicin with dose metrics considerations
    Li, Hequn
    Yuan, Haitao
    Middleton, Alistair
    Li, Jin
    Nicol, Beate
    Carmichael, Paul
    Guo, Jiabin
    Peng, Shuangqing
    Zhang, Qiang
    TOXICOLOGY IN VITRO, 2021, 74
  • [48] Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk
    Gertz, Michael
    Tsamandouras, Nikolaos
    Saell, Carolina
    Houston, J. Brian
    Galetin, Aleksandra
    PHARMACEUTICAL RESEARCH, 2014, 31 (09) : 2367 - 2382
  • [49] Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk
    Michael Gertz
    Nikolaos Tsamandouras
    Carolina Säll
    J. Brian Houston
    Aleksandra Galetin
    Pharmaceutical Research, 2014, 31 : 2367 - 2382
  • [50] Computational Predictions of Mycophenolic Acid Exposure after Oral Administration using a Joined In Vitro-In Vivo Extrapolation and Physiologically-Based Pharmacokinetic Modeling Approach in Caucasian and Chinese Healthy Volunteers and Patients With Varying Degree of Renal Impairment
    Joshi, Rujuta
    Venkataramanan, Raman
    Kalluri, Hari Varun
    TRANSPLANTATION, 2017, 101 (05) : S13 - S14